In a region where obesity has long pressed against the limits of available treatment, Saudi Arabia's drug authority has approved Foundaio — the first once-daily oral GLP-1 medication cleared for use in the Kingdom. The approval marks a quiet but meaningful turn in how modern medicine delivers one of its most sought-after therapies: not by needle, but by pill. Clinical evidence from nearly five thousand trial participants suggests the drug can meaningfully reduce body weight, though regulators are clear that it works best as a companion to changed habits, not a replacement for them.
Saudi SFDA approves first daily oral weight-loss drug Foundaio for obesity
A daily pill fits into the rhythm of everyday life in ways a weekly injection cannot.
Mark
Why does it matter that this is a pill instead of an injection? Aren't the results essentially the same?
Mimi
The mechanism is identical, but the experience is entirely different. An injection you do once a week or once a month—it's a ritual, a commitment you make on a schedule. A daily pill fits into the rhythm of taking vitamins or blood pressure medication. For some people, that removes a psychological barrier. For others, it's just easier to remember.
Mark
The weight loss numbers—11.2 percent for people without diabetes, 9.6 percent for those with it. Are those considered good results?
Mimi
They're substantial. A person weighing 100 kilograms would lose roughly 11 kilograms. That's not a transformation, but it's enough to improve blood pressure, reduce joint stress, and shift how the body metabolizes glucose. The placebo groups lost 2 percent, so the drug is doing real work.
Mark
What about the side effects? Nausea, hair loss, fatigue—that sounds rough.
Mimi
Most of it is temporary. The gastrointestinal symptoms hit hardest when you're ramping up the dose, then they settle down. Hair loss and fatigue are less common and less predictable. The real constraint is the contraindication—if you have a family history of thyroid cancer, you simply cannot take this drug. That's a hard line.
Mark
Why the thyroid cancer restriction?
Mimi
GLP-1 drugs activate receptors that exist throughout the body, including in thyroid tissue. In animal studies, there were signals of thyroid tumors at high doses. It's a precaution. The regulatory authority is saying: we don't fully understand the long-term risk in people with genetic predisposition, so we're not taking the chance.
Mark
So this is really only for people who are committed to diet and exercise too?
Mimi
Exactly. The drug is a tool, not a cure. Without the behavioral changes, you're just masking the appetite signal. The trials showed that—people on placebo still lost 2 percent because they were in a structured program with diet and exercise guidance. The drug amplifies that effect, but it doesn't replace it.
Il Polso
- Millions of adults managing obesity in Saudi Arabia have until now faced a binary choice between injectable therapies or going without GLP-1 treatment altogether — Foundaio breaks that impasse.
- Phase 3 trials enrolling over 4,700 participants showed the 36mg dose cutting body weight by 11.2% in non-diabetic patients and 9.6% in those with Type 2 diabetes, dwarfing placebo results.
- Gastrointestinal side effects — nausea, constipation, vomiting — are common early on, and a mandatory dose-escalation period means patients must navigate discomfort before reaching therapeutic levels.
- Hard safety limits apply: anyone with a personal or family history of certain thyroid cancers is excluded, and the drug requires ongoing medical supervision — it cannot be self-managed.
- The drug now enters a real-world test as physicians begin matching it to patients who can pair it with the dietary and exercise commitments that make its clinical promise translate into lasting results.
In a region where obesity has long pressed against the limits of available treatment, Saudi Arabia's drug authority has approved Foundaio — the first once-daily oral GLP-1 medication cleared for use in the Kingdom. The approval marks a quiet but meaningful turn in how modern medicine delivers one of its most sought-after therapies: not by needle, but by pill. Clinical evidence from nearly five thousand trial participants suggests the drug can meaningfully reduce body weight, though regulators are clear that it works best as a companion to changed habits, not a replacement for them.
Saudi Arabia's Food and Drug Authority has approved Foundaio, an oral tablet that activates the GLP-1 receptor system — the same biological pathway behind the injectable weight-loss drugs that have reshaped obesity medicine in recent years. The active ingredient, orforglipron, is taken once daily, offering patients an alternative to weekly or monthly injections.
The approval followed review of two large Phase 3 trials spanning 72 weeks. Among 3,127 obese adults without diabetes, those on the highest 36mg dose lost an average of 11.2% of their body weight, against 2.1% for placebo. A second trial of 1,613 adults with both obesity and Type 2 diabetes showed 9.6% weight reduction at the same dose, compared to 2.5% on placebo. The drug works by signaling satiety earlier, regulating blood sugar, and reducing overall intake — but regulators stressed it must be paired with diet and exercise to be effective.
Side effects during the dose-escalation phase are predominantly gastrointestinal: nausea, constipation, diarrhea, and vomiting, alongside reports of bloating, fatigue, and hair loss. Most were mild to moderate and eased as patients adjusted. Importantly, the drug is contraindicated for anyone with a personal or family history of certain thyroid cancers, and medical supervision throughout treatment is mandatory.
For Saudi Arabia's healthcare landscape, the approval expands the toolkit available to physicians and patients alike. The convenience of a daily pill taken at home may draw patients who have avoided injectable therapies, but the drug's true measure will come as it enters clinical practice and meets the full complexity of real-world weight management.
Saudi Arabia's drug regulator has cleared a new weapon in the fight against obesity: a pill that patients can swallow once a day instead of injecting themselves weekly or monthly. The medication, called Foundaio, works by activating the same biological pathway that has made injectable weight-loss drugs so popular in recent years—the GLP-1 receptor system—but delivers the active ingredient orforglipron through an oral tablet.
The Saudi Food and Drug Authority announced the approval after reviewing data from two large clinical trials that tested the drug's safety and effectiveness over 72 weeks. In the first study, researchers enrolled 3,127 adults living with obesity who did not have diabetes. Those who took the highest tested dose of 36 milligrams lost an average of 11.2 percent of their body weight, while people given a placebo lost only 2.1 percent. The second trial followed 1,613 adults who had both obesity and Type 2 diabetes. At the same 36 mg dose, these patients achieved an average weight reduction of 9.6 percent compared to 2.5 percent in the placebo group.
The drug's mechanism is straightforward in principle: it signals the body to feel fuller sooner, helps regulate blood sugar, and reduces overall food intake. The regulatory authority emphasized that Foundaio is not a standalone treatment. Patients must combine it with a healthy diet and regular exercise to see results. The approval process included a thorough examination of the drug's quality, safety profile, and clinical evidence before regulators gave it the green light.
Like most medications in this class, Foundaio comes with a roster of side effects that patients should expect, at least initially. The most common complaints during trials were gastrointestinal in nature: nausea, constipation, diarrhea, vomiting, indigestion, and abdominal pain. Some patients also reported bloating, hair loss, and fatigue. The good news is that most of these effects were mild to moderate in severity and tended to fade as patients' bodies adjusted during the dose-escalation phase. Still, the regulatory authority flagged important safety restrictions. The drug cannot be used by anyone with a personal or family history of certain thyroid cancers or related hereditary conditions. Medical supervision and regular follow-up appointments are mandatory—this is not a medication patients can simply start and manage on their own.
The approval represents a significant shift in how obesity treatment is delivered in the region. Until now, patients seeking GLP-1 therapy have relied on injectable formulations that require weekly or monthly administration. An oral option taken daily offers convenience and may appeal to patients who prefer not to use needles. For Saudi Arabia's healthcare system and the millions of adults struggling with weight management, the availability of another tool—especially one that can be taken at home with a glass of water—expands the treatment landscape. The real test will come as the drug enters the market and physicians begin prescribing it to patients who meet the criteria and can commit to the lifestyle changes that make it effective.
Citazioni salienti
The medication must not be used by patients with a personal or family history of certain thyroid cancers or related hereditary syndromes, and treatment should only be undertaken under medical supervision with regular follow-up.— Saudi Food and Drug Authority
Vuoi la storia completa?
Leggi l'originale su zawya.com ↗
Health & Medicine